SRZN
Surrozen Inc. · NASDAQ
- Market cap
- $642.7M
- Shares out
- 21.0M
Surrozen Inc. (SRZN) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 19 wire items for SRZN, including 7 13D/G filings, 6 SEC filings and 3 press releases and news items. The most recent was published Nov 18, 2026.
SRZN rankings
Financial highlights
Full financials- Revenue, TTM
- $10.53M
- Revenue growth
- +192.1%
- Net income, TTM
- -$390.21M
- Net margin
- -3706.4%
- Free cash flow, TTM
- -$30.77M
- Cash
- $100.35M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks36+129%
2026-05-242026-11-15
Mix2590d
- SEC Filings8(32%)
- 13D/G7(28%)
- Other6(24%)
- Insider2(8%)
- Offering1(4%)
- Earnings1(4%)
Activity · 52 weeks9952 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form S-3 filed by Surrozen Inc.S-3 - Surrozen, Inc./DE (0001824893) (Filer)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form 424B5 filed by Surrozen Inc.424B5 - Surrozen, Inc./DE (0001824893) (Filer)
- SECSurrozen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Surrozen, Inc./DE (0001824893) (Filer)
- 13D/GSEC Form SCHEDULE 13G filed by Surrozen Inc.SCHEDULE 13G - Surrozen, Inc./DE (0001824893) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form FWP filed by Surrozen Inc.FWP - Surrozen, Inc./DE (0001824893) (Subject)
- PRSurrozen Announces Pricing of $60 Million Underwritten Offering of Common StockSOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the pricing of an underwritten offering of 1,894,540 shares of its common stock at an offering price of $31.67 per share. The gross proceeds to Surrozen from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Surrozen, are expected to be $60 million. All the shares in the offering are being sold by Surrozen. The offering
- SECSEC Form 10-Q filed by Surrozen Inc.10-Q - Surrozen, Inc./DE (0001824893) (Filer)
- SECSurrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Reports Third Quarter 2026 Financial Results and Provides Business UpdateFirst patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation of SZN-8141 in DME Topline data from DUET Phase 1b expected in second half of 2027; Phase 2a topline data expected in 2028 Second tranche of March 2025 PIPE and ATM transaction totaling approximately $118.9 million in net proceeds in October 2026 extend anticipated cash runway into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to har
- PRSurrozen to Present at Upcoming Healthcare Investor ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim’s 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 Fireside Chat at 1:30 PM Pacific Time / 4:30 PM Eastern Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investo
- 13D/GAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- INSIDERSEC Form 4 filed by Surrozen Inc.4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Surrozen Inc.4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form 8-K filed by Surrozen Inc.8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 MillionSOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the closing of the second and final tranche of its March 2025 private placement of securities. The second closing generated approximately $95.1 million in gross proceeds, before deducting placement agent fees and other offering expenses. The closing followed the achievement of the second closing milestone under the Company’s March 2025 securities purchase agreement, which was
- SECSurrozen Inc. filed SEC Form 8-K: Other Events8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaFirst patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bi
- PRSurrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaSOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody, for the treatment of diabetic macular edema (DME). "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular dis
- PRSurrozen to Present at Upcoming Healthcare Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences. 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 Fireside Chat at 6:10 AM Pacific Time/9:10 AM Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 Fireside Chat at 10:50 AM Pacific Time/1:50 PM Eastern Time In
SRZN FAQ
10 questionsWhat does Surrozen Inc. do?
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific...What is the latest news on SRZN?
In the last 30 days Quantisnow tracked 19 wire items for SRZN: 7 13D/G filings, 6 SEC filings, 3 press releases and news items and 2 insider trades. The most recent was published on November 18, 2026.What is SRZN revenue?
Surrozen Inc. (SRZN) reported $10.53M of revenue for the twelve months ended Sep 30, 2026. That is up 192.1% from the year before. Revenue for fiscal 2025 was $3.48M.Is SRZN profitable?
No. Surrozen Inc. reported a net loss of $390.21M for the twelve months ended Sep 30, 2026.How much cash and debt does SRZN have?
Surrozen Inc. reported $100.35M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SRZN stock trade?
Surrozen Inc. (SRZN) is listed on NASDAQ.What sector and industry is SRZN in?
Surrozen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about SRZN?
Across the last 8 analyst actions on Surrozen Inc., there was 1 upgrade and 0 downgrades. The most recent action was from William Blair: Outperform with a $51.00 price target on 2026-08-20. Recent price targets range from $11.00 to $51.00.What companies are similar to SRZN?
Notable peers in the same industry include RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.), MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.), AMGN (Amgen Inc.). Compare SRZN side-by-side with any of them on Quantisnow.How can I track SRZN on Quantisnow?
Quantisnow aggregates Surrozen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRZN to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change